Supreme showdown in Rx data case this month

Share this article:
Can Vermont bar companies from mining doctors' prescribing data and selling it to drug makers, unless doctors consent, or does such a law violate the First Amendment?
That's the question the Supreme Court is scheduled to take up April 26 when it hears arguments for and against reversing the Second Circuit's decision in Sorrell v. IMS Health. The outcome, expected in June, is likely to resolve the constitutionality of Vermont's statute and similar laws in New Hampshire and Maine, notwithstanding minor differences.
The US Department of Justice, 34 states and the District of Columbia joined Vermont AG William Sorrell in filing briefs supporting his state's law.
Several medical groups did too: the American Academy of Family Practitioners, American Academy of Pediatrics and the New England Journal of Medicine.
Regarding these “friend of the court” briefs, Vermont assistant AG Bridget Asay told MM&M:“It's an important representation of how much doctors care about this issue.”  
The Supreme Court decision to hear the case follows a victory for data providers in Vermont last November. In that state, a federal appeals court reversed a district court ruling that limited the commercial exchange of prescriber data.
The Second US Circuit Court of Appeals ruled that the law in Vermont infringed on First Amendment protections by limiting the free exchange of commercial information. In December, Sorrell filed a petition with the high court, which then agreed to hear the case.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?